ArticleCureus2025
Knowledge and Adherence to Alendronate Administration Among Postmenopausal Osteoporosis Patients: A Cross-Sectional Study From a Tertiary Care Facility in Colombo South.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Compliance with alendronate treatment in postmenopausal women is inadequate due to intricate dosing protocols, resulting in diminished therapeutic effectiveness and heightened fracture risk. Although prior research has recorded adherence rates, few have determined independent determinants through multivariate analysis, especially within South Asian communities. This study sought to ascertain adherence rates, identify independent determinants of adherence, evaluate awareness of drug-food combinations, and examine the influence of various counseling sources on compliance. Methods A cross-sectional study was performed at Colombo South Teaching Hospital, Sri Lanka, from January to December 2024, involving 300 postmenopausal women diagnosed with osteoporosis who had been administered alendronate 70 mg weekly for a minimum duration of six months. The sample size was determined with the Lwanga and Lemeshow formula, presuming a 50% adherence rate, a 95% confidence interval, and a 5.7% margin of error. A validated questionnaire evaluated compliance with seven dosing instructions, understanding of 13 drug-food-medication combinations, side effects, and sources of patient education. Multivariate logistic regression discovered independent determinants of optimal adherence. Results The average age was 67.4±8.9 years. Only 48 participants (16.0%) attained optimal adherence (compliance score ≥6/7), with a median compliance score of 4.0 (IQR: 3.0-5.0). In multivariate analysis, the independent predictors of optimal adherence included pharmacist counseling (adjusted OR=3.24, 95% CI: 1.87-5.61, p<0.001), comprehensive understanding of instructions (adjusted OR=2.89, 95% CI: 1.65-5.06, p<0.001), tertiary education (adjusted OR=2.15, 95% CI: 1.23-3.76, p=0.007), and suburban residence (adjusted OR=1.87, 95% CI: 1.12-3.14, p=0.017). The median knowledge score was 6.0 out of 13, with an interquartile range of 5.0 to 7.0. Significant knowledge deficiencies encompassed erroneous notions regarding co-administration with liquids other than plain water (154 participants, 51.3%). Adverse effects were reported by 187 individuals (62.3%), primarily gastrointestinal problems. Conclusions Compliance with alendronate is significantly low among postmenopausal women in Sri Lanka. Pharmacist advice and comprehensive comprehension of instructions were identified as the most significant modifiable determinants of adherence. Healthcare systems must establish organized pharmaceutical care programs and create instructional materials suitable for health literacy to enhance osteoporosis treatment results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.